280 related articles for article (PubMed ID: 31254268)
1. Advances in Targeted Therapies for Triple-Negative Breast Cancer.
McCann KE; Hurvitz SA; McAndrew N
Drugs; 2019 Jul; 79(11):1217-1230. PubMed ID: 31254268
[TBL] [Abstract][Full Text] [Related]
2. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions.
Mai N; Abuhadra N; Jhaveri K
Clin Breast Cancer; 2023 Dec; 23(8):784-799. PubMed ID: 37336650
[TBL] [Abstract][Full Text] [Related]
3. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer.
Kumari L; Mishra L; Patel P; Sharma N; Gupta GD; Kurmi BD
J Drug Target; 2023 Dec; 31(9):889-907. PubMed ID: 37539789
[TBL] [Abstract][Full Text] [Related]
4. Landmark trials in the medical oncology management of metastatic breast cancer.
Lu P; Santa-Maria CA; Ballinger TJ; Sheng JY
Semin Oncol; 2021 Jun; 48(3):246-258. PubMed ID: 34364700
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
Song X; Fang C; Dai Y; Sun Y; Qiu C; Lin X; Xu R
Br J Cancer; 2024 May; 130(8):1239-1248. PubMed ID: 38355840
[TBL] [Abstract][Full Text] [Related]
6. Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.
Hamilton N; Marquez-Garban D; Mah VH; Elshimali Y; Elashoff D; Garon EB; Vadgama J; Pietras R
Crit Rev Oncog; 2015; 20(5-6):373-90. PubMed ID: 27279236
[TBL] [Abstract][Full Text] [Related]
7. New strategies for triple-negative breast cancer--deciphering the heterogeneity.
Mayer IA; Abramson VG; Lehmann BD; Pietenpol JA
Clin Cancer Res; 2014 Feb; 20(4):782-90. PubMed ID: 24536073
[TBL] [Abstract][Full Text] [Related]
8. Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification.
Tovey H; Cheang MCU
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31769425
[TBL] [Abstract][Full Text] [Related]
9. The evolvement of breast cancer therapies: What we have done and where all these head off.
Nurlaila I; Pambudi S
Saudi Med J; 2024 Apr; 45(4):331-340. PubMed ID: 38657992
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in managing triple-negative breast cancers.
Bengala C
F1000 Med Rep; 2009 Sep; 1():. PubMed ID: 20948704
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
12. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
Medina MA; Oza G; Sharma A; Arriaga LG; Hernández Hernández JM; Rotello VM; Ramirez JT
Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32245065
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer: recent treatment advances.
Bergin ART; Loi S
F1000Res; 2019; 8():. PubMed ID: 31448088
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
[TBL] [Abstract][Full Text] [Related]
16. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges.
Khan MA; Jain VK; Rizwanullah M; Ahmad J; Jain K
Drug Discov Today; 2019 Nov; 24(11):2181-2191. PubMed ID: 31520748
[TBL] [Abstract][Full Text] [Related]
17. Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020.
Azim HA; Ghosn M; Oualla K; Kassem L
Breast J; 2020 Jan; 26(1):69-80. PubMed ID: 31872557
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
19. The Landscape of Targeted Therapies in TNBC.
Vagia E; Mahalingam D; Cristofanilli M
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32276534
[TBL] [Abstract][Full Text] [Related]
20. Triple negative breast cancer: A thorough review of biomarkers.
da Silva JL; Cardoso Nunes NC; Izetti P; de Mesquita GG; de Melo AC
Crit Rev Oncol Hematol; 2020 Jan; 145():102855. PubMed ID: 31927455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]